Kilitch Drugs (India) Balance Sheet Health
Financial Health criteria checks 5/6
Kilitch Drugs (India) has a total shareholder equity of ₹1.9B and total debt of ₹324.1M, which brings its debt-to-equity ratio to 17.2%. Its total assets and total liabilities are ₹2.6B and ₹709.5M respectively. Kilitch Drugs (India)'s EBIT is ₹154.0M making its interest coverage ratio 3.4. It has cash and short-term investments of ₹588.5M.
Key information
17.2%
Debt to equity ratio
₹324.12m
Debt
| Interest coverage ratio | 3.4x |
| Cash | ₹588.52m |
| Equity | ₹1.88b |
| Total liabilities | ₹709.50m |
| Total assets | ₹2.59b |
Recent financial health updates
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Recent updates
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar
Jul 23Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16Financial Position Analysis
Short Term Liabilities: KILITCH's short term assets (₹1.5B) exceed its short term liabilities (₹707.8M).
Long Term Liabilities: KILITCH's short term assets (₹1.5B) exceed its long term liabilities (₹1.7M).
Debt to Equity History and Analysis
Debt Level: KILITCH has more cash than its total debt.
Reducing Debt: KILITCH's debt to equity ratio has increased from 10.9% to 17.2% over the past 5 years.
Debt Coverage: KILITCH's debt is well covered by operating cash flow (64.9%).
Interest Coverage: KILITCH's interest payments on its debt are well covered by EBIT (3.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 04:14 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kilitch Drugs (India) Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|